Paying hospitals to cut the drugs budget

HSE has introduced a new, incentivsed scheme to increase the use of biosimilars in hospitals

Take-up of biosimilars in the Irish health system has been held back by the lack of Government encouragement and inertia among medical practitioners. Photograph: Benis Arapovic/Getty

Take-up of biosimilars in the Irish health system has been held back by the lack of Government encouragement and inertia among medical practitioners. Photograph: Benis Arapovic/Getty

 

Efforts to pull together a national policy on biosimilars remain stymied somewhere in the Department of Health but at least some moves are finally being made to tap the potential for cutting the State’s medicines budget.

Biosimilars are like-for-like versions of expensive new generation biologic drugs that have come off patent. While not generics, which are identical copies of older drugs, biosimilars act in the same way and with the same safety profile as their branded rivals.

But take-up of biosimilars in the Irish health system has been painfully slow, held back by the lack of Government encouragement and inertia among medical practitioners.

It has become an increasingly contentious issue for drug companies – torn between promoting their own branded products but also looking at the State to create financial headroom to purchase expensive new therapies.

The issue has been highlighted by the failure of Spinraza – the only approved therapy in Europe for a rare and often fatal muscle-wasting disease, spinal muscular atrophy, that affects children in particular – to secure approval for use in Ireland recently at the second time of asking.

Now, the HSE has moved to incentivise consultants to use biosimilars for two of the most expensive drugs in the medicines budget – rheumatoid arthritis therapies Humira and Enbrel.

Doctors are being offered a €500 incentive for every new patient prescribed biosimilar alternatives or for existing patients who are transferred to the lower cost therapies.

The money will go back into the hospitals to help bulk out stretched budgets.

From Saturday, consultants will have to use an online high-tech hub to prescribe for the conditions. The biosimilar options will be among the default options. It is understood that consultants, who want to continue prescribing the more expensive brand name drugs, will be forced to take a more complex and labour intensive process.

It’s a small step but a step nonetheless in the right direction.

* The headline on this article was amended on June 1st, 2019

The Irish Times Logo
Commenting on The Irish Times has changed. To comment you must now be an Irish Times subscriber.
SUBSCRIBE
GO BACK
Error Image
The account details entered are not currently associated with an Irish Times subscription. Please subscribe to sign in to comment.
Comment Sign In

Forgot password?
The Irish Times Logo
Thank you
You should receive instructions for resetting your password. When you have reset your password, you can Sign In.
The Irish Times Logo
Please choose a screen name. This name will appear beside any comments you post. Your screen name should follow the standards set out in our community standards.
Screen Name Selection

Hello

Please choose a screen name. This name will appear beside any comments you post. Your screen name should follow the standards set out in our community standards.

The Irish Times Logo
Commenting on The Irish Times has changed. To comment you must now be an Irish Times subscriber.
SUBSCRIBE
Forgot Password
Please enter your email address so we can send you a link to reset your password.

Sign In

Your Comments
We reserve the right to remove any content at any time from this Community, including without limitation if it violates the Community Standards. We ask that you report content that you in good faith believe violates the above rules by clicking the Flag link next to the offending comment or by filling out this form. New comments are only accepted for 3 days from the date of publication.